Carolyn Bertozzi and Versant's new biotech breaks cover with $94M to use protein degraders in ADCs
15 Feb 2024
ADCAcquisitionPhase 1
In the
bustling world of antibody-drug conjugates
, few biopharmas have revealed ambitions for combining antibodies with protein degraders, rather than chemo or other cytotoxic drugs.
Firefly Bio was unveiled Thursday with a $94 million Series A from Versant Ventures’ discovery unit in Basel, Switzerland, as well as backing from MPM BioImpact, Decheng Capital and Eli Lilly.
ADCs have been one of biopharma’s hottest areas for dealmaking. Lilly has inked two acquisitions in the ADC field in recent quarters. And late last year, Bristol Myers Squibb paid $100 million upfront to snag a Phase I-cleared ADC with a similar approach to Firefly’s,
out of Orum Therapeutics
. But using degraders in ADCs is nascent.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.